NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Cimeio Therapeutics

Cimeio Therapeutics

Private
BaselHealthcare & Life Scienceshttps://www.cimeio.com/

Last Round

Series A

Apr 13, 2022

Total Funding Raised

$50M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Cimeio Therapeutics is a biotechnology company that develops Shielded-Cell & Immunotherapy Pairs (SCIP) to treat hematologic malignancies, autoimmune disorders, and genetic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

cell therapygene editingCAR T-cell therapyCAR Tcell shieldingshielded cellsepitope engineeringhematopoietic cell therapyoncologybiotech platformtargeted cancer therapynext-gen immunotherapyprecision medicinedrug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Cimeio Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Cimeio Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Cimeio Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AApr 13, 2022

Cimeio Therapeutics Investors

Notable investors and investment history

Cimeio Therapeutics investors
InvestorRounds
Versant VenturesSeries A
BaseLaunchSeries A
University of BaselSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 23, 2026

    Monthly visitors grew 246% MoM to 2.3K.

Cimeio Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Cimeio Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Cimeio Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBasel
Employee Range16
Year Founded2020
Last FundingApr 13, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.